Fate Therapeutics, Inc.
Fate Therapeutics, Inc. (FATE) Stock Competitors & Peer Comparison
See (FATE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FATE | $2.29 | -3.18% | 266.2M | -1.99 | -$1.15 | N/A |
| VRTX | $427.23 | +0.68% | 108.8B | 25.37 | $16.85 | N/A |
| REGN | $712.31 | +1.43% | 74.3B | 17.59 | $40.99 | +0.49% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $786.67 | -1.01% | 50B | 41.31 | $19.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $295.08 | -2.00% | 40.4B | 76.32 | $3.97 | N/A |
| RVMD | $142.67 | -3.08% | 32.1B | -25.36 | -$5.95 | N/A |
| INSM | $104.00 | -25.42% | 29.6B | -21.38 | -$6.41 | N/A |
| UTHR | $575.69 | +0.61% | 26.1B | 21.40 | $27.86 | N/A |
Stock Comparison
FATE vs VRTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, VRTX has a market cap of 108.8B. Regarding current trading prices, FATE is priced at $2.29, while VRTX trades at $427.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas VRTX's P/E ratio is 25.37. In terms of profitability, FATE's ROE is -0.55%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, FATE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check VRTX's competition here
FATE vs REGN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, REGN has a market cap of 74.3B. Regarding current trading prices, FATE is priced at $2.29, while REGN trades at $712.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas REGN's P/E ratio is 17.59. In terms of profitability, FATE's ROE is -0.55%, compared to REGN's ROE of +0.14%. Regarding short-term risk, FATE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check REGN's competition here
FATE vs VRNA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, FATE is priced at $2.29, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas VRNA's P/E ratio is -102.80. In terms of profitability, FATE's ROE is -0.55%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, FATE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check VRNA's competition here
FATE vs ARGX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ARGX has a market cap of 50B. Regarding current trading prices, FATE is priced at $2.29, while ARGX trades at $786.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ARGX's P/E ratio is 41.31. In terms of profitability, FATE's ROE is -0.55%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, FATE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ARGX's competition here
FATE vs SGEN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, FATE is priced at $2.29, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas SGEN's P/E ratio is -57.19. In terms of profitability, FATE's ROE is -0.55%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, FATE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check SGEN's competition here
FATE vs ALNY Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ALNY has a market cap of 40.4B. Regarding current trading prices, FATE is priced at $2.29, while ALNY trades at $295.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ALNY's P/E ratio is 76.32. In terms of profitability, FATE's ROE is -0.55%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, FATE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ALNY's competition here
FATE vs RVMD Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RVMD has a market cap of 32.1B. Regarding current trading prices, FATE is priced at $2.29, while RVMD trades at $142.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RVMD's P/E ratio is -25.36. In terms of profitability, FATE's ROE is -0.55%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, FATE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RVMD's competition here
FATE vs INSM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, INSM has a market cap of 29.6B. Regarding current trading prices, FATE is priced at $2.29, while INSM trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas INSM's P/E ratio is -21.38. In terms of profitability, FATE's ROE is -0.55%, compared to INSM's ROE of -1.68%. Regarding short-term risk, FATE is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for FATE.Check INSM's competition here
FATE vs UTHR Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, UTHR has a market cap of 26.1B. Regarding current trading prices, FATE is priced at $2.29, while UTHR trades at $575.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas UTHR's P/E ratio is 21.40. In terms of profitability, FATE's ROE is -0.55%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, FATE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check UTHR's competition here
FATE vs BNTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BNTX has a market cap of 23.9B. Regarding current trading prices, FATE is priced at $2.29, while BNTX trades at $92.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BNTX's P/E ratio is -16.01. In terms of profitability, FATE's ROE is -0.55%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, FATE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BNTX's competition here
FATE vs RPRX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RPRX has a market cap of 21.7B. Regarding current trading prices, FATE is priced at $2.29, while RPRX trades at $49.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RPRX's P/E ratio is 28.48. In terms of profitability, FATE's ROE is -0.55%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, FATE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RPRX's competition here
FATE vs ROIV Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ROIV has a market cap of 20.6B. Regarding current trading prices, FATE is priced at $2.29, while ROIV trades at $28.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ROIV's P/E ratio is -24.62. In terms of profitability, FATE's ROE is -0.55%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, FATE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ROIV's competition here
FATE vs BGNE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, FATE is priced at $2.29, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BGNE's P/E ratio is -22.55. In terms of profitability, FATE's ROE is -0.55%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, FATE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BGNE's competition here
FATE vs INCY Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, INCY has a market cap of 19.9B. Regarding current trading prices, FATE is priced at $2.29, while INCY trades at $97.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas INCY's P/E ratio is 14.06. In terms of profitability, FATE's ROE is -0.55%, compared to INCY's ROE of +0.29%. Regarding short-term risk, FATE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check INCY's competition here
FATE vs MRNA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MRNA has a market cap of 19.3B. Regarding current trading prices, FATE is priced at $2.29, while MRNA trades at $47.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MRNA's P/E ratio is -6.72. In terms of profitability, FATE's ROE is -0.55%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, FATE is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MRNA's competition here
FATE vs DNA-WT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, FATE is priced at $2.29, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, FATE's ROE is -0.55%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, FATE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check DNA-WT's competition here
FATE vs GMAB Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, GMAB has a market cap of 17.2B. Regarding current trading prices, FATE is priced at $2.29, while GMAB trades at $27.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas GMAB's P/E ratio is 18.12. In terms of profitability, FATE's ROE is -0.55%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, FATE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check GMAB's competition here
FATE vs ASND Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ASND has a market cap of 14.5B. Regarding current trading prices, FATE is priced at $2.29, while ASND trades at $233.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ASND's P/E ratio is -53.36. In terms of profitability, FATE's ROE is -0.55%, compared to ASND's ROE of +1.28%. Regarding short-term risk, FATE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ASND's competition here
FATE vs JAZZ Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, JAZZ has a market cap of 14.3B. Regarding current trading prices, FATE is priced at $2.29, while JAZZ trades at $224.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas JAZZ's P/E ratio is 2075.36. In terms of profitability, FATE's ROE is -0.55%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, FATE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check JAZZ's competition here
FATE vs SMMT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, SMMT has a market cap of 13.8B. Regarding current trading prices, FATE is priced at $2.29, while SMMT trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas SMMT's P/E ratio is -11.23. In terms of profitability, FATE's ROE is -0.55%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, FATE is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check SMMT's competition here
FATE vs BBIO Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, FATE is priced at $2.29, while BBIO trades at $67.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BBIO's P/E ratio is -18.01. In terms of profitability, FATE's ROE is -0.55%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, FATE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BBIO's competition here
FATE vs IONS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, IONS has a market cap of 12.7B. Regarding current trading prices, FATE is priced at $2.29, while IONS trades at $75.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas IONS's P/E ratio is -38.23. In terms of profitability, FATE's ROE is -0.55%, compared to IONS's ROE of -0.59%. Regarding short-term risk, FATE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check IONS's competition here
FATE vs KRTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, FATE is priced at $2.29, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas KRTX's P/E ratio is -28.09. In terms of profitability, FATE's ROE is -0.55%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, FATE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check KRTX's competition here
FATE vs EXEL Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, FATE is priced at $2.29, while EXEL trades at $45.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas EXEL's P/E ratio is 16.12. In terms of profitability, FATE's ROE is -0.55%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, FATE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check EXEL's competition here
FATE vs MDGL Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, FATE is priced at $2.29, while MDGL trades at $513.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MDGL's P/E ratio is -41.91. In terms of profitability, FATE's ROE is -0.55%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, FATE is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MDGL's competition here
FATE vs AXSM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, AXSM has a market cap of 11.5B. Regarding current trading prices, FATE is priced at $2.29, while AXSM trades at $217.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas AXSM's P/E ratio is -59.68. In terms of profitability, FATE's ROE is -0.55%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, FATE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check AXSM's competition here
FATE vs RNAM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, FATE is priced at $2.29, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RNAM's P/E ratio is -17.39. In terms of profitability, FATE's ROE is -0.55%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, FATE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RNAM's competition here
FATE vs ARWR Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, FATE is priced at $2.29, while ARWR trades at $76.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ARWR's P/E ratio is 49.47. In terms of profitability, FATE's ROE is -0.55%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, FATE is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ARWR's competition here
FATE vs BMRN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, FATE is priced at $2.29, while BMRN trades at $53.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BMRN's P/E ratio is 39.29. In terms of profitability, FATE's ROE is -0.55%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, FATE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BMRN's competition here
FATE vs RXDX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, FATE is priced at $2.29, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RXDX's P/E ratio is -56.47. In terms of profitability, FATE's ROE is -0.55%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, FATE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RXDX's competition here
FATE vs CYTK Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, FATE is priced at $2.29, while CYTK trades at $74.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CYTK's P/E ratio is -11.44. In terms of profitability, FATE's ROE is -0.55%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, FATE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CYTK's competition here
FATE vs IMGN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, FATE is priced at $2.29, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas IMGN's P/E ratio is -111.55. In terms of profitability, FATE's ROE is -0.55%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, FATE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check IMGN's competition here
FATE vs IBRX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, FATE is priced at $2.29, while IBRX trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas IBRX's P/E ratio is -20.97. In terms of profitability, FATE's ROE is -0.55%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, FATE is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check IBRX's competition here
FATE vs KRYS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, KRYS has a market cap of 8.5B. Regarding current trading prices, FATE is priced at $2.29, while KRYS trades at $280.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas KRYS's P/E ratio is 38.63. In terms of profitability, FATE's ROE is -0.55%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, FATE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check KRYS's competition here
FATE vs BPMC Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, FATE is priced at $2.29, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BPMC's P/E ratio is -51.58. In terms of profitability, FATE's ROE is -0.55%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, FATE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BPMC's competition here
FATE vs ABVX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, FATE is priced at $2.29, while ABVX trades at $125.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ABVX's P/E ratio is -22.33. In terms of profitability, FATE's ROE is -0.55%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, FATE is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ABVX's competition here
FATE vs PCVX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, FATE is priced at $2.29, while PCVX trades at $50.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas PCVX's P/E ratio is -10.14. In terms of profitability, FATE's ROE is -0.55%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, FATE is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check PCVX's competition here
FATE vs CERE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, FATE is priced at $2.29, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CERE's P/E ratio is -16.47. In terms of profitability, FATE's ROE is -0.55%, compared to CERE's ROE of -0.72%. Regarding short-term risk, FATE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CERE's competition here
FATE vs HALO Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, FATE is priced at $2.29, while HALO trades at $64.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas HALO's P/E ratio is 25.93. In terms of profitability, FATE's ROE is -0.55%, compared to HALO's ROE of +0.93%. Regarding short-term risk, FATE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check HALO's competition here
FATE vs NUVL Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, FATE is priced at $2.29, while NUVL trades at $100.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas NUVL's P/E ratio is -17.83. In terms of profitability, FATE's ROE is -0.55%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, FATE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check NUVL's competition here
FATE vs MTSR Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, FATE is priced at $2.29, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MTSR's P/E ratio is -23.58. In terms of profitability, FATE's ROE is -0.55%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, FATE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MTSR's competition here
FATE vs TECH Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, FATE is priced at $2.29, while TECH trades at $48.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas TECH's P/E ratio is 89.44. In terms of profitability, FATE's ROE is -0.55%, compared to TECH's ROE of +0.05%. Regarding short-term risk, FATE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check TECH's competition here
FATE vs PRAX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, FATE is priced at $2.29, while PRAX trades at $327.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas PRAX's P/E ratio is -25.09. In terms of profitability, FATE's ROE is -0.55%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, FATE is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check PRAX's competition here
FATE vs KYMR Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, FATE is priced at $2.29, while KYMR trades at $84.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas KYMR's P/E ratio is -24.09. In terms of profitability, FATE's ROE is -0.55%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, FATE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check KYMR's competition here
FATE vs MRUS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, FATE is priced at $2.29, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MRUS's P/E ratio is -17.05. In terms of profitability, FATE's ROE is -0.55%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, FATE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MRUS's competition here
FATE vs CELC Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CELC has a market cap of 6.7B. Regarding current trading prices, FATE is priced at $2.29, while CELC trades at $127.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CELC's P/E ratio is -31.81. In terms of profitability, FATE's ROE is -0.55%, compared to CELC's ROE of -2.03%. Regarding short-term risk, FATE is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CELC's competition here
FATE vs ACLX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, FATE is priced at $2.29, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ACLX's P/E ratio is -28.27. In terms of profitability, FATE's ROE is -0.55%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, FATE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ACLX's competition here
FATE vs TGTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, TGTX has a market cap of 6.7B. Regarding current trading prices, FATE is priced at $2.29, while TGTX trades at $43.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas TGTX's P/E ratio is 15.15. In terms of profitability, FATE's ROE is -0.55%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, FATE is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check TGTX's competition here
FATE vs PTGX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, FATE is priced at $2.29, while PTGX trades at $99.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas PTGX's P/E ratio is -50.73. In terms of profitability, FATE's ROE is -0.55%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, FATE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check PTGX's competition here
FATE vs RYTM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, FATE is priced at $2.29, while RYTM trades at $94.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RYTM's P/E ratio is -30.87. In terms of profitability, FATE's ROE is -0.55%, compared to RYTM's ROE of -2.04%. Regarding short-term risk, FATE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RYTM's competition here
FATE vs RETA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, FATE is priced at $2.29, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RETA's P/E ratio is -66.29. In terms of profitability, FATE's ROE is -0.55%, compared to RETA's ROE of +0.47%. Regarding short-term risk, FATE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RETA's competition here
FATE vs BLTE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, FATE is priced at $2.29, while BLTE trades at $148.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BLTE's P/E ratio is -67.68. In terms of profitability, FATE's ROE is -0.55%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, FATE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BLTE's competition here
FATE vs CNTA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, FATE is priced at $2.29, while CNTA trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CNTA's P/E ratio is -27.13. In terms of profitability, FATE's ROE is -0.55%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, FATE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CNTA's competition here
FATE vs ALKS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, FATE is priced at $2.29, while ALKS trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ALKS's P/E ratio is 39.23. In terms of profitability, FATE's ROE is -0.55%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, FATE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ALKS's competition here
FATE vs IMVT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, IMVT has a market cap of 5.8B. Regarding current trading prices, FATE is priced at $2.29, while IMVT trades at $27.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas IMVT's P/E ratio is -10.74. In terms of profitability, FATE's ROE is -0.55%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, FATE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check IMVT's competition here
FATE vs COGT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, FATE is priced at $2.29, while COGT trades at $34.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas COGT's P/E ratio is -16.54. In terms of profitability, FATE's ROE is -0.55%, compared to COGT's ROE of -0.83%. Regarding short-term risk, FATE is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check COGT's competition here
FATE vs CGON Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, FATE is priced at $2.29, while CGON trades at $67.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CGON's P/E ratio is -32.69. In terms of profitability, FATE's ROE is -0.55%, compared to CGON's ROE of -0.23%. Regarding short-term risk, FATE is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CGON's competition here
FATE vs CDTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, FATE is priced at $2.29, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CDTX's P/E ratio is -19.77. In terms of profitability, FATE's ROE is -0.55%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, FATE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CDTX's competition here
FATE vs CORT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CORT has a market cap of 5.6B. Regarding current trading prices, FATE is priced at $2.29, while CORT trades at $50.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CORT's P/E ratio is 148.91. In terms of profitability, FATE's ROE is -0.55%, compared to CORT's ROE of +0.08%. Regarding short-term risk, FATE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CORT's competition here
FATE vs PTCT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, FATE is priced at $2.29, while PTCT trades at $64.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas PTCT's P/E ratio is 7.76. In terms of profitability, FATE's ROE is -0.55%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, FATE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check PTCT's competition here
FATE vs ABCM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, FATE is priced at $2.29, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, FATE's ROE is -0.55%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, FATE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ABCM's competition here
FATE vs MIRM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, FATE is priced at $2.29, while MIRM trades at $99.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MIRM's P/E ratio is -233.83. In terms of profitability, FATE's ROE is -0.55%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, FATE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MIRM's competition here
FATE vs ISEE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, FATE is priced at $2.29, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ISEE's P/E ratio is -22.44. In terms of profitability, FATE's ROE is -0.55%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, FATE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ISEE's competition here
FATE vs CAI Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, FATE is priced at $2.29, while CAI trades at $19.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CAI's P/E ratio is -5.94. In terms of profitability, FATE's ROE is -0.55%, compared to CAI's ROE of +0.25%. Regarding short-term risk, FATE is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CAI's competition here
FATE vs SRRK Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, FATE is priced at $2.29, while SRRK trades at $45.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas SRRK's P/E ratio is -14.31. In terms of profitability, FATE's ROE is -0.55%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, FATE is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check SRRK's competition here
FATE vs LEGN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, FATE is priced at $2.29, while LEGN trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas LEGN's P/E ratio is -17.86. In terms of profitability, FATE's ROE is -0.55%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, FATE is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check LEGN's competition here
FATE vs CRSP Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, FATE is priced at $2.29, while CRSP trades at $52.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CRSP's P/E ratio is -8.93. In terms of profitability, FATE's ROE is -0.55%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, FATE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CRSP's competition here
FATE vs APLS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, FATE is priced at $2.29, while APLS trades at $41.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas APLS's P/E ratio is 228.14. In terms of profitability, FATE's ROE is -0.55%, compared to APLS's ROE of +0.08%. Regarding short-term risk, FATE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check APLS's competition here
FATE vs APGE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, FATE is priced at $2.29, while APGE trades at $81.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas APGE's P/E ratio is -20.06. In terms of profitability, FATE's ROE is -0.55%, compared to APGE's ROE of -0.37%. Regarding short-term risk, FATE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check APGE's competition here
FATE vs FBIOX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, FATE is priced at $2.29, while FBIOX trades at $25.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas FBIOX's P/E ratio is N/A. In terms of profitability, FATE's ROE is -0.55%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, FATE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check FBIOX's competition here
FATE vs TERN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, FATE is priced at $2.29, while TERN trades at $52.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas TERN's P/E ratio is -51.42. In terms of profitability, FATE's ROE is -0.55%, compared to TERN's ROE of -0.20%. Regarding short-term risk, FATE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check TERN's competition here
FATE vs LGND Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, FATE is priced at $2.29, while LGND trades at $213.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas LGND's P/E ratio is 37.87. In terms of profitability, FATE's ROE is -0.55%, compared to LGND's ROE of +0.14%. Regarding short-term risk, FATE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check LGND's competition here
FATE vs XENE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, FATE is priced at $2.29, while XENE trades at $56.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas XENE's P/E ratio is -13.43. In terms of profitability, FATE's ROE is -0.55%, compared to XENE's ROE of -0.56%. Regarding short-term risk, FATE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check XENE's competition here
FATE vs FOLD Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, FATE is priced at $2.29, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas FOLD's P/E ratio is -161.00. In terms of profitability, FATE's ROE is -0.55%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, FATE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check FOLD's competition here
FATE vs MANE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, FATE is priced at $2.29, while MANE trades at $111.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MANE's P/E ratio is -46.03. In terms of profitability, FATE's ROE is -0.55%, compared to MANE's ROE of -0.76%. Regarding short-term risk, FATE is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MANE's competition here
FATE vs AKRO Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, FATE is priced at $2.29, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas AKRO's P/E ratio is -14.57. In terms of profitability, FATE's ROE is -0.55%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, FATE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check AKRO's competition here
FATE vs ALPN Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, FATE is priced at $2.29, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ALPN's P/E ratio is -101.52. In terms of profitability, FATE's ROE is -0.55%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, FATE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ALPN's competition here
FATE vs SYRE Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, FATE is priced at $2.29, while SYRE trades at $71.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas SYRE's P/E ratio is -36.87. In terms of profitability, FATE's ROE is -0.55%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, FATE is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check SYRE's competition here
FATE vs CRNX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CRNX has a market cap of 4.4B. Regarding current trading prices, FATE is priced at $2.29, while CRNX trades at $40.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CRNX's P/E ratio is -8.43. In terms of profitability, FATE's ROE is -0.55%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, FATE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CRNX's competition here
FATE vs KNSA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, FATE is priced at $2.29, while KNSA trades at $55.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas KNSA's P/E ratio is 61.26. In terms of profitability, FATE's ROE is -0.55%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, FATE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check KNSA's competition here
FATE vs OPT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, FATE is priced at $2.29, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas OPT's P/E ratio is -1.52. In terms of profitability, FATE's ROE is -0.55%, compared to OPT's ROE of +0.88%. Regarding short-term risk, FATE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check OPT's competition here
FATE vs TVTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, FATE is priced at $2.29, while TVTX trades at $42.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas TVTX's P/E ratio is -89.53. In terms of profitability, FATE's ROE is -0.55%, compared to TVTX's ROE of -0.58%. Regarding short-term risk, FATE is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check TVTX's competition here
FATE vs MRTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, FATE is priced at $2.29, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas MRTX's P/E ratio is -4.82. In terms of profitability, FATE's ROE is -0.55%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, FATE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check MRTX's competition here
FATE vs EWTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, FATE is priced at $2.29, while EWTX trades at $35.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas EWTX's P/E ratio is -22.69. In terms of profitability, FATE's ROE is -0.55%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, FATE is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check EWTX's competition here
FATE vs TLX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, FATE is priced at $2.29, while TLX trades at $10.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas TLX's P/E ratio is -555.75. In terms of profitability, FATE's ROE is -0.55%, compared to TLX's ROE of -0.02%. Regarding short-term risk, FATE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check TLX's competition here
FATE vs RYZB Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, FATE is priced at $2.29, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas RYZB's P/E ratio is -57.86. In terms of profitability, FATE's ROE is -0.55%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, FATE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check RYZB's competition here
FATE vs VKTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, FATE is priced at $2.29, while VKTX trades at $30.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas VKTX's P/E ratio is -7.78. In terms of profitability, FATE's ROE is -0.55%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, FATE is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check VKTX's competition here
FATE vs CPRX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CPRX has a market cap of 3.7B. Regarding current trading prices, FATE is priced at $2.29, while CPRX trades at $31.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CPRX's P/E ratio is 18.17. In terms of profitability, FATE's ROE is -0.55%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, FATE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CPRX's competition here
FATE vs CBAY Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, FATE is priced at $2.29, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas CBAY's P/E ratio is -32.81. In terms of profitability, FATE's ROE is -0.55%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, FATE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check CBAY's competition here
FATE vs LQDA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, FATE is priced at $2.29, while LQDA trades at $41.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas LQDA's P/E ratio is -52.67. In terms of profitability, FATE's ROE is -0.55%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, FATE is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check LQDA's competition here
FATE vs ACAD Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, FATE is priced at $2.29, while ACAD trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ACAD's P/E ratio is 9.34. In terms of profitability, FATE's ROE is -0.55%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, FATE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ACAD's competition here
FATE vs NAMS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, FATE is priced at $2.29, while NAMS trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas NAMS's P/E ratio is -18.03. In terms of profitability, FATE's ROE is -0.55%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, FATE is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check NAMS's competition here
FATE vs SWTX Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, FATE is priced at $2.29, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas SWTX's P/E ratio is -13.78. In terms of profitability, FATE's ROE is -0.55%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, FATE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check SWTX's competition here
FATE vs DNTH Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, FATE is priced at $2.29, while DNTH trades at $84.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas DNTH's P/E ratio is -21.52. In terms of profitability, FATE's ROE is -0.55%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, FATE is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check DNTH's competition here
FATE vs ERAS Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, ERAS has a market cap of 3.4B. Regarding current trading prices, FATE is priced at $2.29, while ERAS trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas ERAS's P/E ratio is -24.77. In terms of profitability, FATE's ROE is -0.55%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, FATE is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check ERAS's competition here
FATE vs BEAM Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, FATE is priced at $2.29, while BEAM trades at $30.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas BEAM's P/E ratio is -39.93. In terms of profitability, FATE's ROE is -0.55%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, FATE is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check BEAM's competition here
FATE vs VCYT Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, FATE is priced at $2.29, while VCYT trades at $40.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas VCYT's P/E ratio is 38.20. In terms of profitability, FATE's ROE is -0.55%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, FATE is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check VCYT's competition here
FATE vs DNLI Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, FATE is priced at $2.29, while DNLI trades at $19.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas DNLI's P/E ratio is -6.86. In terms of profitability, FATE's ROE is -0.55%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, FATE is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check DNLI's competition here
FATE vs KLRA Comparison May 2026
FATE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FATE stands at 266.2M. In comparison, KLRA has a market cap of 3.2B. Regarding current trading prices, FATE is priced at $2.29, while KLRA trades at $23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FATE currently has a P/E ratio of -1.99, whereas KLRA's P/E ratio is -19.58. In terms of profitability, FATE's ROE is -0.55%, compared to KLRA's ROE of N/A. Regarding short-term risk, FATE is more volatile compared to KLRA. This indicates potentially higher risk in terms of short-term price fluctuations for FATE.Check KLRA's competition here